Many lines of evidence showed that IL-6 is capable of enhancing EMT via JAK-STAT3 signaling in a variety of human cancers such as breast cancer [32,45], head and neck squamous cell carcinoma [46], pancreatic cancer [47] and CRC [48]. This evidence concerns the gene IL6 and familial pancreatic carcinoma.